의약품 판매 수탁기관 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 치료 분야별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report By Services (Personal, Non-personal Promotion), By Therapeutic Area, By End Use (Pharma, Biopharma Companies), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

의약품 판매 수탁기관 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 의약품 판매 수탁기관 세계 시장 규모는 2030년까지 181억 4,000만 달러에 달할 것이며, 2025-2030년 8.83%의 CAGR로 확대될 것으로 추정됩니다.

의약품 판매 수탁기관(CSO)의 높은 판매 수탁을 위한 신기술 채택률, 바이오의약품 및 저분자 의약품 판매 확대에 대한 최종사용자의 관심 증가, 자체 판매 관련 비용 절감에 대한 수요 급증은 산업 성장을 뒷받침하는 주요 요인 중 일부입니다. 최근 몇 년 동안 신약 출시 수가 증가하고 있습니다.

예를 들어, IQVIA의 연구개발 동향 보고서에 따르면 2021년에는 전 세계적으로 84개의 새로운 유효물질이 출시되었으며, 이는 지난 5년 동안 2배로 증가한 수치입니다. 세계 신약 출시의 증가는 판매 수탁 서비스에 대한 수요를 향상시킬 것으로 예상되며 산업의 성장을 지원할 가능성이 높습니다. 처방약의 매출은 꾸준히 증가하고 있습니다. 예를 들어, Evaluate Pharma에 따르면 2021년 세계 처방약 매출은 1조 660억 달러, 2028년에는 1조 6,120억 달러에 달할 것으로 예상됩니다. 제약 기업의 판매 수요 증가는 팬데믹 이후 의약품 CSO 서비스에 대한 수요 증가로 이어질 것으로 예상됩니다.

의약품 판매 수탁기관 시장 보고서 하이라이트

• 서비스별로는 2024년 개인 프로모션 부문이 산업을 주도했습니다. 제약기업의 연구개발 활동이 활발해짐에 따라 신약 출시가 증가할 것으로 예상되며, 신약 승인은 이 부문의 성장을 견인할 것으로 보입니다.
• 2024년 제약사의 최종 용도 부문이 가장 큰 매출 점유율을 차지했는데, 이는 제약사 간 제품 판매 경쟁이 치열해지면서 영업 활동을 지원하는 효율적인 팀에 대한 수요가 높아졌기 때문으로 분석됩니다.
• 북미는 2024년 가장 큰 매출 점유율을 차지했습니다. 이 지역, 특히 미국에서는 지난 몇 년 동안 상당한 수의 의약품이 출시되었으며, 이는 이 지역의 성장을 뒷받침하는 중요한 요인 중 하나입니다.
• 또한, 이 지역의 공공 기관은 자금 지원을 통한 연구개발 활동 지원에 꾸준히 노력하고 있습니다. 이는 이 지역의 성장을 더욱 뒷받침하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조 시장 전망
• 시장 동향과 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 산업 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 의약품 판매 수탁기관 시장 : 서비스별, 추정·동향 분석

• 부문 대시보드
• 의약품 판매 수탁기관 시장, 서비스 변동 분석
• 의약품 판매 수탁기관 시장 규모와 동향 분석, 서비스별, 2018-2030년
• 개인 프로모션
  • 프로모션 영업 팀
  • 주요 어카운트 관리
  • 공실 관리
• 비개인 프로모션
  • Medical Affairs Solutions
  • Remote Medical Science Liaisons
  • Nurse Educators
  • 기타

제5장 의약품 판매 수탁기관 시장 : 치료 분야별, 추정·동향 분석

• 부문 대시보드
• 의약품 판매 수탁기관 시장, 치료 분야 변동 분석
• 의약품 판매 수탁기관 시장 규모와 동향 분석, 치료 분야별, 2018-2030년
• 종양학
• 심혈관
• 신경학
• 감염증
• 대사장애
• 정형외과 질환
• 기타

제6장 의약품 판매 수탁기관 시장 : 최종 용도별, 추정·동향 분석

• 부문 대시보드
• 의약품 판매 수탁기관 시장, 최종 용도 변동 분석
• 의약품 판매 수탁기관 규모와 동향 분석, 최종 용도별, 2018-2030년
• 제약회사
• 바이오의약품 기업

제7장 지역 비즈니스 분석

• 지역 대시보드
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 북미
  • 북미의 의약품 판매 수탁기관 시장, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 의약품 판매 수탁기관 시장, 2018-2030년
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 의약품 판매 수탁기관 시장, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 의약품 판매 수탁기관 시장, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 의약품 판매 수탁기관 시장, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업 분류
• 기업 시장 상황 분석, 2024년
• 기업 개요
  • CMIC Holdings Co., Ltd.
  • Axxelus
  • EPS Corp.
  • QFR Solutions
  • MaBico
  • Mednext Pharma Pvt. Ltd.
  • Peak Pharma Solutions Inc.
  • IQVIA, Inc.
  • Promoveo Health
  • Syneous Health

ksm

영문 목차

영문목차

Pharmaceutical Contract Sales Organizations Market Growth & Trends:

The global pharmaceutical contract sales organizations market size is estimated to reach USD 18.14 billion by 2030, expanding at a CAGR of 8.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.

For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.

Pharmaceutical Contract Sales Organizations Market Report Highlights:

• Based on service, the personal promotion segment dominated the industry in 2024. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
• The pharmaceutical companies end-use segment held the largest revenue share in 2024 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
• North America held the largest revenue share in 2024. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region's growth
• Moreover, the region's public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region's growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Contract Sales Organizations Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Pharmaceutical Contract Sales Organizations Market; Service Movement Analysis
• 4.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Personal Promotion
  • 4.4.1. Personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Promotional sales team
    • 4.4.2.1. Promotional sales team market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Key account management
    • 4.4.3.1. Key account management market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Vacancy management
    • 4.4.4.1. Vacancy management market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Non-personal promotion
  • 4.5.1. Non-personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Medical affairs solutions
    • 4.5.2.1. Medical affairs solutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Remote medical science liaisons
    • 4.5.3.1. Remote medical science liaisons market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Nurse educators
    • 4.5.4.1. Nurse educators market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Contract Sales Organizations Market: Therapeutic Areas Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Pharmaceutical Contract Sales Organizations Market; Therapeutic Areas Movement Analysis
• 5.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular
  • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Neurology
  • 5.6.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Infectious Diseases
  • 5.7.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Metabolic Disorders
  • 5.8.1. Metabolic Disorders market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Orthopedic Diseases
  • 5.9.1. Orthopedic Diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Contract Sales Organizations Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Pharmaceutical Contract Sales Organizations Market; End Use Movement Analysis
• 6.3. Pharmaceutical Contract Sales Organizations Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Germany pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. UK pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. South Korea pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Australia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Thailand pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. CMIC Holdings Co., Ltd.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Axxelus
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. EPS Corp.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. QFR Solutions
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. MaBico
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Mednext Pharma Pvt. Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Peak Pharma Solutions Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. IQVIA, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Promoveo Health
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Syneous Health
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives

관련자료